Please login to the form below

Not currently logged in
Email:
Password:

AZ licensing agreement with Aurobindo

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca to supply certain generic products for emerging markets

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca (AZ) to supply the Anglo-Swedish drugmaker with certain generic products to be sold in emerging markets.

The generics involved in the agreement include several solid dosage and sterile products and offer therapeutic care in such areas as anti-infectives, as well as covering conditions affecting the cardiovascular system (CVS) and the central nervous system (CNS).

Financial terms of the deal were not disclosed.

India-based Aurobindo manufactures generic pharmaceuticals and active pharmaceutical ingredients, with products marketed in over 125 countries.

This is Aurobindo's second deal with a major global pharmaceutical company to supply drugs for emerging markets following an agreement with Pfizer in 2009.

Speaking on the deal, Kaushik Banerjee, head of branded generics operations at AstraZeneca said "These agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business."

Aurobindo chairman P V Ramprasad Reddy said: “Aurobindo's proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca which will accelerate our growth plans and support our earnings."

7th September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...